Technical Analysis for SWTX - SpringWorks Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 39.28 | -4.20% | -1.72 |
SWTX closed down 4.2 percent on Thursday, February 6, 2025, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Reached Overbought | Strength | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
MACD Bullish Centerline Cross | Bullish | -4.20% | |
Pocket Pivot | Bullish Swing Setup | -4.20% | |
Multiple of Ten Bullish | Other | -4.20% | |
Crossed Above 20 DMA | Bullish | 2.29% | |
Crossed Above 200 DMA | Bullish | 2.29% | |
Crossed Above 50 DMA | Bullish | 2.29% | |
New Uptrend | Bullish | 2.29% |
Alert | Time |
---|---|
Down 3% | about 9 hours ago |
60 Minute Opening Range Breakdown | about 10 hours ago |
Down 2 % | about 15 hours ago |
Down 1% | about 15 hours ago |
Rose Above Previous Day's High | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: 02/20/2025
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Rare Diseases Drug Development
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Rare Diseases Drug Development
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 53.92 |
52 Week Low | 28.21 |
Average Volume | 1,364,014 |
200-Day Moving Average | 37.55 |
50-Day Moving Average | 38.15 |
20-Day Moving Average | 36.89 |
10-Day Moving Average | 37.36 |
Average True Range | 2.65 |
RSI (14) | 55.56 |
ADX | 28.4 |
+DI | 30.46 |
-DI | 11.10 |
Chandelier Exit (Long, 3 ATRs) | 37.70 |
Chandelier Exit (Short, 3 ATRs) | 39.90 |
Upper Bollinger Bands | 41.83 |
Lower Bollinger Band | 31.96 |
Percent B (%b) | 0.74 |
BandWidth | 26.75 |
MACD Line | 0.38 |
MACD Signal Line | -0.09 |
MACD Histogram | 0.4712 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 43.02 | ||||
Resistance 3 (R3) | 43.41 | 42.57 | 42.39 | ||
Resistance 2 (R2) | 42.57 | 41.62 | 42.37 | 42.18 | |
Resistance 1 (R1) | 40.92 | 41.03 | 40.50 | 40.53 | 41.98 |
Pivot Point | 40.08 | 40.08 | 39.87 | 39.88 | 40.08 |
Support 1 (S1) | 38.43 | 39.13 | 38.01 | 38.04 | 36.58 |
Support 2 (S2) | 37.59 | 38.54 | 37.39 | 36.38 | |
Support 3 (S3) | 35.94 | 37.59 | 36.17 | ||
Support 4 (S4) | 35.55 |